SO-YOUNG INTERNATIONAL INC.

(SY)
  Report
Delayed Nasdaq  -  04:00 2022-08-15 pm EDT
0.9224 USD   -4.43%
08/09So-Young to Report Second Quarter 2022 Financial Results on August 16, 2022
GL
08/03Asian ADRs Move Lower in Wednesday Trading
MT
07/27Asian ADRs Move Higher in Wednesday Trading
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

HOOKIPA Pharma to Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021

11/03/2021 | 07:19am EDT

NEW YORK and VIENNA, Austria, Nov. 03, 2021 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release third quarter 2021 financial results before the market opens on Wednesday, November 10, 2021.

The Company will not be conducting a conference call in conjunction with this earnings release.

About HOOKIPA
HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company developing a new class of immunotherapeutics based on its proprietary arenavirus platform that reprograms the body’s immune system.

HOOKIPA’s proprietary arenavirus-based technologies, non-replicating and replicating, induce robust antigen-specific CD8+ T cells and pathogen-neutralizing antibodies. HOOKIPA’s viral vectors target antigen presenting cells in vivo to activate the immune system. Both technologies enable repeat administration to augment and refresh immune responses. As a monotherapy not used in combination, our replicating arenavirus technology has the potential to induce CD8+ T cell response levels previously not achieved by other immuno-therapy approaches.

HOOKIPA is building a proprietary immuno-oncology pipeline by targeting virally mediated cancer antigens, self-antigens and next-generation antigens. The lead replicating arenavirus oncology product candidates, HB-201 and HB-202, are in development for the treatment of Human Papilloma Virus 16-positive cancers in a Phase 1/2 clinical trial.

HOOKIPA’s non-replicating prophylactic Cytomegalovirus (CMV) vaccine candidate, HB-101, is currently in a Phase 2 clinical trial for patients awaiting kidney transplantation. To expand its infectious disease portfolio, HOOKIPA entered into a collaboration and licensing agreement with Gilead Sciences, Inc. to research arenavirus-based functional cures for HIV and chronic Hepatitis B infections.

Find out more about HOOKIPA online at www.hookipapharma.com.

For further information, please contact: 
MediaInvestors
Astrid van ErvenMatt Beck
Senior Manager - CommunicationsExecutive Director - Investor Relations
Astrid.vanErven@hookipapharma.comMatthew.Beck@hookipapharma.com

 

 


All news about SO-YOUNG INTERNATIONAL INC.
08/09So-Young to Report Second Quarter 2022 Financial Results on August 16, 2022
GL
08/03Asian ADRs Move Lower in Wednesday Trading
MT
07/27Asian ADRs Move Higher in Wednesday Trading
MT
07/18SO YOUNG INTERNATIONAL : Young Announces Receipt of Minimum Bid Price Notice from Nasdaq -..
PU
07/18So-Young International Gets Nasdaq Notice for Non-Compliance With Minimum Bid Price Req..
MT
07/18So-Young Announces Receipt of Minimum Bid Price Notice from Nasdaq
GL
07/18So-Young Announces Receipt of Minimum Bid Price Notice from Nasdaq
AQ
06/20SO-YOUNG INTERNATIONAL INC.(NASDAQGM : SY) dropped from S&P Global BMI Index
CI
06/03Asian ADRs Move Sharply Lower in Friday Trading
MT
05/31Asian ADRs Move Higher in Tuesday Trading
MT
More news
Analyst Recommendations on SO-YOUNG INTERNATIONAL INC.
More recommendations
Financials
Sales 2022 1 113 M 164 M 164 M
Net income 2022 -290 M -42,8 M -42,8 M
Net Debt 2022 - - -
P/E ratio 2022 -2,18x
Yield 2022 -
Capitalization 659 M 97,3 M 97,3 M
Capi. / Sales 2022 0,59x
Capi. / Sales 2023 0,43x
Nbr of Employees 2 085
Free-Float 40,6%
Chart SO-YOUNG INTERNATIONAL INC.
Duration : Period :
So-Young International Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SO-YOUNG INTERNATIONAL INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 6,25 CNY
Average target price 15,27 CNY
Spread / Average Target 144%
EPS Revisions
Managers and Directors
Xing Jin Chairman, Chief Executive & Operating Officer
Min Yu Chief Financial Officer
Xuejian Li Chief Technology Officer & Director
Zhao Xuan Yang Independent Director
Chao He Independent Director
Sector and Competitors
1st jan.Capi. (M$)
SO-YOUNG INTERNATIONAL INC.-69.74%102